Curating the evidence in haematopoietic stem cell transplantation. Free monthly Stem Cell Evidence Alert http://bit.ly/2HMQtb5 @stemcellevidence@fediscience.org #MedSky https://bsky.app/profile/stemcellevidence.bsky.socialhttps://bsky.app/profile/stemcellevidence.bsky.social/post/3mumaihvstc2u🟣 New from the #StemCellEvidence alert: 📑 CD19/CD22 bivalent CAR T cells in children, adolescents and young adults with B-ALL: final phase 1 trial results by Silbert et al. 🔗 Link in the comments #MedSky03 Sep 2026 10:28 +0000at://did:plc:b6x546parybrgexu7wi4rdhj/app.bsky.feed.post/3mumaihvstc2uhttps://bsky.app/profile/stemcellevidence.bsky.social/post/3mumaevligc2u🆕 From the #StemCellEvidence alert: 📑 CMV-specific T-cell receptor-engineered T-cell therapy as first-line treatment for CMV reactivation after haploidentical hematopoietic stem cell transplantation: a phase 2 trial by Tang et al. 🔗 Link in the comments #MedSky03 Sep 2026 10:26 +0000at://did:plc:b6x546parybrgexu7wi4rdhj/app.bsky.feed.post/3mumaevligc2uhttps://bsky.app/profile/stemcellevidence.bsky.social/post/3mujhwqsbnk2c🟣 New from the #StemCellEvidence alert: 📑 CD19/CD22 bivalent CAR T cells in children, adolescents and young adults with B-ALL: final phase 1 trial results by Silbert et al. 🔗 Link in the comments #MedSky02 Sep 2026 08:03 +0000at://did:plc:b6x546parybrgexu7wi4rdhj/app.bsky.feed.post/3mujhwqsbnk2chttps://bsky.app/profile/stemcellevidence.bsky.social/post/3mujhrdne3c2c🆕 From the #StemCellEvidence alert: 📑 CMV-specific T-cell receptor-engineered T-cell therapy as first-line treatment for CMV reactivation after haploidentical hematopoietic stem cell transplantation: a phase 2 trial by Tang et al. 🔗 Link in the comments #MedSky02 Sep 2026 08:00 +0000at://did:plc:b6x546parybrgexu7wi4rdhj/app.bsky.feed.post/3mujhrdne3c2chttps://bsky.app/profile/stemcellevidence.bsky.social/post/3mugwce23jk24🟣 New from the #StemCellEvidence alert: 📑 Randomized Trial of Two Fractionation Schedules of Myeloablative Busulfan with Fludarabine and Cladribine in Acute Myeloid Leukemia or Myelodysplastic Syndromes by Popat et al. 🔗 Link in the comments #MedSky01 Sep 2026 07:42 +0000at://did:plc:b6x546parybrgexu7wi4rdhj/app.bsky.feed.post/3mugwce23jk24https://bsky.app/profile/stemcellevidence.bsky.social/post/3mugw5yfmcs24🆕From the #StemCellEvidence alert: 📑Reduced-Dose Post-Transplant Cyclophosphamide as Graft-Versus-Host Disease Prophylaxis in Matched Donor Allogeneic Stem Cell Transplantation: A #SystematicReview of Efficacy and Toxicity by Shafqat et al. 🔗Link in the comments #MedSky01 Sep 2026 07:40 +0000at://did:plc:b6x546parybrgexu7wi4rdhj/app.bsky.feed.post/3mugw5yfmcs24https://bsky.app/profile/stemcellevidence.bsky.social/post/3mu5ba6jphk2y🟣 New from the #StemCellEvidence alert: 📑 Incidence, molecular and clinical characteristics of donor-derived hematologic malignancies after allogeneic stem cell transplantation for myeloid malignancies by Perekhrestenko et al. 🔗 Link in the comments #MedSky28 Aug 2026 11:31 +0000at://did:plc:b6x546parybrgexu7wi4rdhj/app.bsky.feed.post/3mu5ba6jphk2yhttps://bsky.app/profile/stemcellevidence.bsky.social/post/3mu5azre4tc2y🆕 From the #StemCellEvidence alert: 📑 Chronic GVHD Consortium CATCH Study: Incidence, initial presentation and risk factors for chronic GVHD development by Pidala et al. 🔗 Link in the comments #MedSky28 Aug 2026 11:28 +0000at://did:plc:b6x546parybrgexu7wi4rdhj/app.bsky.feed.post/3mu5azre4tc2yhttps://bsky.app/profile/stemcellevidence.bsky.social/post/3mu327qza4c2l🟣 New from the #StemCellEvidence alert: 📑 Donor age as a dual-risk factor for donor safety and recipient survival in allogeneic haematopoietic stem cell transplantation by Nishiwaki et al. 🔗 Link in the comments #MedSky27 Aug 2026 14:20 +0000at://did:plc:b6x546parybrgexu7wi4rdhj/app.bsky.feed.post/3mu327qza4c2lhttps://bsky.app/profile/stemcellevidence.bsky.social/post/3mu322qs6ok2l🆕 From the #StemCellEvidence alert: 📑 Evaluation of ex-utero collection for umbilical cord blood banking: A randomized clinical trial comparing cord blood quality with the in-utero technique by Ozbey et al. 🔗 Link in the comments #MedSky27 Aug 2026 14:18 +0000at://did:plc:b6x546parybrgexu7wi4rdhj/app.bsky.feed.post/3mu322qs6ok2lhttps://bsky.app/profile/stemcellevidence.bsky.social/post/3mtyrqui4qs2d🟣 New from the #StemCellEvidence alert: 📑 Rituximab Maintenance Added to Ibrutinib-Containing Therapy in Younger, Untreated Patients With Mantle Cell Lymphoma: Results From the TRIANGLE Trial by Ladetto et al. 🔗 Link in the comments #MedSky26 Aug 2026 16:44 +0000at://did:plc:b6x546parybrgexu7wi4rdhj/app.bsky.feed.post/3mtyrqui4qs2dhttps://bsky.app/profile/stemcellevidence.bsky.social/post/3mtyrkvmr7c2d🆕 From the #StemCellEvidence alert: 📑 Comparison of Allo-HSCT outcomes after CAR-T therapy versus chemotherapy in pediatric patients with relapsed/refractory B-ALL: a retrospective study by Li et al. 🔗 Link in the comments #MedSky26 Aug 2026 16:40 +0000at://did:plc:b6x546parybrgexu7wi4rdhj/app.bsky.feed.post/3mtyrkvmr7c2dhttps://bsky.app/profile/stemcellevidence.bsky.social/post/3mtvsj476qk2j📄New from the #StemCellEvidence alert: Donor cell-derived haematological neoplasms after allogeneic haematopoietic cell transplantation: recommendations from the EBMT Practice Harmonisation and Guidelines Committee by Gurnari et al. 🔗Link in the replies #MedSky25 Aug 2026 12:19 +0000at://did:plc:b6x546parybrgexu7wi4rdhj/app.bsky.feed.post/3mtvsj476qk2jhttps://bsky.app/profile/stemcellevidence.bsky.social/post/3mtvsdmxfjk2j📄From the #StemCellEvidence alert: High-dose chemotherapy followed by autologous stem-cell transplantation versus non-myeloablative consolidation in primary CNS lymphoma (MATRix/IELSG43): a randomised phase 3 trial by Illerhaus et al. 🔗Link in the replies #MedSky25 Aug 2026 12:16 +0000at://did:plc:b6x546parybrgexu7wi4rdhj/app.bsky.feed.post/3mtvsdmxfjk2jhttps://bsky.app/profile/stemcellevidence.bsky.social/post/3mtt2blt7se2a📄 From the #StemCellEvidence alert: The 2024 EBMT activity report: crossing one million HCTs and 20,000 CAR-T. A landmark in cellular therapy by Greco et al. 🔗 Link in the replies #MedSky24 Aug 2026 10:00 +0000at://did:plc:b6x546parybrgexu7wi4rdhj/app.bsky.feed.post/3mtt2blt7se2ahttps://bsky.app/profile/stemcellevidence.bsky.social/post/3mtt2bkxi7e2o📄 New from the #StemCellEvidence alert: Pretransplant Blinatumomab Is Associated With Reduced Relapse and Improved Disease-Free Survival in Adults With B-Cell ALL Undergoing Allogeneic Hematopoietic Cell Transplantation by Ginosyan et al. 🔗 Link in the replies #MedSky24 Aug 2026 10:00 +0000at://did:plc:b6x546parybrgexu7wi4rdhj/app.bsky.feed.post/3mtt2bkxi7e2ohttps://bsky.app/profile/stemcellevidence.bsky.social/post/3mtlcykyuds25🟣 New from the #StemCellEvidence alert: 📑 Cellular therapy in mantle cell lymphoma: recommendations from the EBMT practice harmonisation and guidelines committee by Dreger et al. 🔗 Link in the comments #MedSky21 Aug 2026 08:15 +0000at://did:plc:b6x546parybrgexu7wi4rdhj/app.bsky.feed.post/3mtlcykyuds25https://bsky.app/profile/stemcellevidence.bsky.social/post/3mtlcvicwn225🆕 From the #StemCellEvidence alert: 📑 Significance of CD34+ Cell Dose on Outcomes of Non-Myeloablative Allogeneic Hematopoietic Cell Transplantation in AML: An Analysis Stratified by MRD Status by Gang et al. 🔗Link in the comments #MedSky21 Aug 2026 08:13 +0000at://did:plc:b6x546parybrgexu7wi4rdhj/app.bsky.feed.post/3mtlcvicwn225https://bsky.app/profile/stemcellevidence.bsky.social/post/3mtj2ghpdik2w🟣 New from the #StemCellEvidence alert: 📑 Donor-specific transplant outcomes from BMT CTN 1702: a multicenter prospective biologic assignment trial by Bashey et al. 🔗 Link in the comments #MedSky20 Aug 2026 10:36 +0000at://did:plc:b6x546parybrgexu7wi4rdhj/app.bsky.feed.post/3mtj2ghpdik2whttps://bsky.app/profile/stemcellevidence.bsky.social/post/3mtj2dakngc2w🆕 From the #StemCellEvidence alert: 📑 Better 10-Year Cerebrovascular Outcome After Transplant Than on Standard-Care in Sickle Cell Anemia: DREPAGREFFE Trial by Bernaudin et al. 🔗 Link in the comments #MedSky20 Aug 2026 10:35 +0000at://did:plc:b6x546parybrgexu7wi4rdhj/app.bsky.feed.post/3mtj2dakngc2w